BIOGEN INC (IDP.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:IDP • US09062X1037

164.25 EUR
+6 (+3.79%)
Last: Feb 6, 2026, 07:00 PM
Fundamental Rating

5

IDP gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 81 industry peers in the Biotechnology industry. IDP has an excellent financial health rating, but there are some minor concerns on its profitability. IDP is cheap, but on the other hand it scores bad on growth. These ratings would make IDP suitable for value investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • IDP had positive earnings in the past year.
  • In the past year IDP had a positive cash flow from operations.
  • IDP had positive earnings in 4 of the past 5 years.
  • IDP had a positive operating cash flow in 4 of the past 5 years.
IDP.DE Yearly Net Income VS EBIT VS OCF VS FCFIDP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

1.2 Ratios

  • With an excellent Return On Assets value of 5.51%, IDP belongs to the best of the industry, outperforming 81.48% of the companies in the same industry.
  • The Return On Equity of IDP (8.84%) is better than 81.48% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 9.70%, IDP belongs to the top of the industry, outperforming 86.42% of the companies in the same industry.
  • IDP had an Average Return On Invested Capital over the past 3 years of 10.57%. This is in line with the industry average of 12.03%.
Industry RankSector Rank
ROA 5.51%
ROE 8.84%
ROIC 9.7%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
IDP.DE Yearly ROA, ROE, ROICIDP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

  • IDP's Profit Margin of 15.98% is amongst the best of the industry. IDP outperforms 82.72% of its industry peers.
  • In the last couple of years the Profit Margin of IDP has declined.
  • IDP has a Operating Margin of 28.50%. This is amongst the best in the industry. IDP outperforms 87.65% of its industry peers.
  • In the last couple of years the Operating Margin of IDP has declined.
  • The Gross Margin of IDP (75.24%) is better than 62.96% of its industry peers.
  • In the last couple of years the Gross Margin of IDP has declined.
Industry RankSector Rank
OM 28.5%
PM (TTM) 15.98%
GM 75.24%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
IDP.DE Yearly Profit, Operating, Gross MarginsIDP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IDP is destroying value.
  • There is no outstanding debt for IDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IDP.DE Yearly Shares OutstandingIDP.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
IDP.DE Yearly Total Debt VS Total AssetsIDP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

  • An Altman-Z score of 3.44 indicates that IDP is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.44, IDP is in the better half of the industry, outperforming 70.37% of the companies in the same industry.
  • IDP has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as IDP would need 2.78 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 2.78, IDP belongs to the best of the industry, outperforming 82.72% of the companies in the same industry.
  • IDP has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.35, IDP is in line with its industry, outperforming 56.79% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 2.78
Altman-Z 3.44
ROIC/WACC0.81
WACC12.01%
IDP.DE Yearly LT Debt VS Equity VS FCFIDP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

  • IDP has a Current Ratio of 2.72. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.72, IDP is in line with its industry, outperforming 56.79% of the companies in the same industry.
  • IDP has a Quick Ratio of 2.04. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of IDP (2.04) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 2.04
IDP.DE Yearly Current Assets VS Current LiabilitesIDP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

1

3. Growth

3.1 Past

  • The earnings per share for IDP have decreased by -7.16% in the last year.
  • The earnings per share for IDP have been decreasing by -14.17% on average. This is quite bad
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-7.14%

3.2 Future

  • Based on estimates for the next years, IDP will show a small growth in Earnings Per Share. The EPS will grow by 1.58% on average per year.
  • The Revenue is expected to decrease by -1.22% on average over the next years.
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y1.58%
Revenue Next Year-5.09%
Revenue Next 2Y-2.76%
Revenue Next 3Y-1.56%
Revenue Next 5Y-1.22%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
IDP.DE Yearly Revenue VS EstimatesIDP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
IDP.DE Yearly EPS VS EstimatesIDP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

7

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 12.67, IDP is valued correctly.
  • Based on the Price/Earnings ratio, IDP is valued cheaply inside the industry as 95.06% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of IDP to the average of the S&P500 Index (27.93), we can say IDP is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 12.73, IDP is valued correctly.
  • 97.53% of the companies in the same industry are more expensive than IDP, based on the Price/Forward Earnings ratio.
  • IDP is valuated cheaply when we compare the Price/Forward Earnings ratio to 27.77, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.67
Fwd PE 12.73
IDP.DE Price Earnings VS Forward Price EarningsIDP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 88.89% of the companies in the same industry are more expensive than IDP, based on the Enterprise Value to EBITDA ratio.
  • IDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. IDP is cheaper than 95.06% of the companies in the same industry.
Industry RankSector Rank
P/FCF 12.56
EV/EBITDA 8.44
IDP.DE Per share dataIDP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • The decent profitability rating of IDP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.48%
EPS Next 3Y3.07%

0

5. Dividend

5.1 Amount

  • No dividends for IDP!.
Industry RankSector Rank
Dividend Yield 0%

BIOGEN INC

FRA:IDP (2/6/2026, 7:00:00 PM)

164.25

+6 (+3.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)04-29
Inst Owners96.04%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap24.10B
Revenue(TTM)N/A
Net Income(TTM)1.61B
Analysts73.33
Price Target165.61 (0.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)6.55%
PT rev (3m)10.11%
EPS NQ rev (1m)2%
EPS NQ rev (3m)1.28%
EPS NY rev (1m)0.25%
EPS NY rev (3m)-1.61%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-0.13%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)0.61%
Valuation
Industry RankSector Rank
PE 12.67
Fwd PE 12.73
P/S 2.82
P/FCF 12.56
P/OCF 11.58
P/B 1.56
P/tB 11.92
EV/EBITDA 8.44
EPS(TTM)12.96
EY7.89%
EPS(NY)12.9
Fwd EY7.85%
FCF(TTM)13.08
FCFY7.96%
OCF(TTM)14.18
OCFY8.63%
SpS58.18
BVpS105.23
TBVpS13.78
PEG (NY)N/A
PEG (5Y)N/A
Graham Number175.18
Profitability
Industry RankSector Rank
ROA 5.51%
ROE 8.84%
ROCE 11.07%
ROIC 9.7%
ROICexc 11.44%
ROICexgc 40.96%
OM 28.5%
PM (TTM) 15.98%
GM 75.24%
FCFM 22.48%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 2.78
Debt/EBITDA 1.73
Cap/Depr 25.04%
Cap/Sales 1.9%
Interest Coverage 250
Cash Conversion 67.56%
Profit Quality 140.63%
Current Ratio 2.72
Quick Ratio 2.04
Altman-Z 3.44
F-Score5
WACC12.01%
ROIC/WACC0.81
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y1.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-7.14%
Revenue Next Year-5.09%
Revenue Next 2Y-2.76%
Revenue Next 3Y-1.56%
Revenue Next 5Y-1.22%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year3.51%
EBIT Next 3Y0.64%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%

BIOGEN INC / IDP.DE FAQ

What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.


What is the valuation status for IDP stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.


What is the profitability of IDP stock?

BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.


What is the financial health of BIOGEN INC (IDP.DE) stock?

The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.


What is the expected EPS growth for BIOGEN INC (IDP.DE) stock?

The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -0.5% in the next year.